Dasatinib

Dasatinib is a prescription kinase inhibitor used in selected leukemias, commonly sold as Sprycel. It interferes with BCR-ABL and other signaling pathways relevant to these diseases. This page covers conventional Sprycel-type oral tablets. It should not be used to transfer instructions automatically to a different dasatinib formulation, because absorption and product-specific recommendations can differ.

Uses and treatment context

Approved uses include defined Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia settings. The disease phase, age group, previous treatments and combination regimen determine eligibility. Pediatric treatment requires the instructions for the exact formulation and a specialist plan. Tablet and oral-suspension instructions should not be treated as interchangeable. An oncology team follows both response and adverse effects rather than relying on symptoms alone.

Stomach medicines are an important interaction

Conventional dasatinib tablets depend on stomach conditions for absorption. The Sprycel label advises against combining them with proton pump inhibitors or H2 blockers. Antacids have a different instruction: simultaneous administration is avoided, and a product-specific separation schedule is needed. Simply moving a proton pump inhibitor to another time of day does not make it equivalent to an antacid. Ask the oncology pharmacist to review prescribed and nonprescription indigestion treatments together.

Other medicines and monitoring

Strong CYP3A inhibitors can increase dasatinib exposure and toxicity; strong inducers can lower exposure and treatment effect. Anticoagulants and medicines that inhibit platelets may add to bleeding risk. Medicines that prolong the QT interval need particular attention, especially when potassium or magnesium is low. High-dose methotrexate is another labeled interaction whose setting must be distinguished from a low-dose prescription. Do not stop or substitute a medicine based only on a search result.

Adverse effects and warning signs

Common problems include low blood cell counts, fluid retention, diarrhea, headache, rash, fatigue, nausea and musculoskeletal discomfort. Important complications include bleeding, fluid around the lungs, cardiovascular toxicity, pulmonary arterial hypertension, QT prolongation and liver injury. New or worsening breathlessness, chest pain, fainting, substantial swelling, fever with illness, serious bleeding, jaundice or a severe rash require assessment. Routine blood tests and symptom checks help identify problems early.

Reproductive safety and practical review

Dasatinib can harm an unborn baby. Pregnancy planning and contraception advice should be reviewed with the prescriber. The U.S. label advises against breastfeeding during treatment and for two weeks after the last dose. No general safe alcohol limit is established here. Bring supplements, cold medicines and stomach remedies to a medication review; absence of a pair record does not establish safety.

Sources checked

• SPRYCEL U.S. prescribing information (DailyMed)
• Sprycel English product information (EMA)
• FDA clinical CYP and transporter interaction examples

Source verification date: 4 November 2026. This is a source-based educational summary, not a claim of independent clinical peer review.